Review

Cancer stem cells and the SHH pathway in malignant melanoma: Therapeutic implications

Volume: 64 Number: 2 June 10, 2025
TR EN

Cancer stem cells and the SHH pathway in malignant melanoma: Therapeutic implications

Abstract

Melanoma is an aggressive skin cancer arising from melanocytes. Melanoma is a complex disease, sourced from genetic and environmental factors. Within melanoma, cancer stem cells (CSCs) play a crucial role in tumor progression, therapeutic resistance, and recurrence due to their capabilities for self-renewal and differentiation. The Sonic Hedgehog (SHH) signaling pathway is an important regulator of CSCs and is essential for cell differentiation and proliferation. Due to the known role in embryonic development and involvement in cancers, SHH pathway significantly affects CSC behavior in malignant melanoma, promoting tumorigenicity, metastasis, and resistance to therapies. This pathway coordinates canonical mechanisms involving Gli transcription factors and non-canonical mechanisms affecting cell migration and cytoskeletal organization. Targeting the SHH pathway has emerged as a promising therapeutic strategy, with inhibitors focusing on components like Smoothened (Smo) and Gli proteins. However, resistance to these inhibitors necessitates further exploration of novel therapeutic combinations. Current research focuses on combining SHH inhibitors with immunotherapies for more effective, long-lasting responses. Targeted medicines, which disrupt SHH processes, attempt to eliminate the fundamental causes of carcinogenesis and increase melanoma patient survival rates.

Keywords

Supporting Institution

Scientific Research Projects Coordination Unit at Ege University

Project Number

20785

Ethical Statement

It is a review study. There is no need for an ethics committee document.

Thanks

Scientific Research Projects Coordination Unit at Ege University

References

  1. Pandiani C, Béranger GE, Leclerc J, Ballotti R, Bertolotto C. Focus on cutaneous and uveal melanoma specificities. Genes Dev. Nisan 2017;31(8):724–43.
  2. Hessler M, Jalilian E, Xu Q, Reddy S, Horton L, Elkin K, vd. Melanoma biomarkers and their potential application for in vivo diagnostic imaging modalities. Int J Mol Sci. 2020;21(24):9583.
  3. Moran B, Silva R, Perry AS, Gallagher WM. Epigenetics of malignant melanoma. Semin Cancer Biol [Internet]. 2018;51:80–8. Available at: https://www.sciencedirect.com/science/article/pii/S1044579X1730130X
  4. Apalla Z, Lallas A, Sotiriou E, Lazaridou E, Ioannides D. Epidemiological trends in skin cancer. Dermatol Pract Concept [Internet]. 30 Nisan 2017;7(2):1–6. Available at: https://pubmed.ncbi.nlm.nih.gov/28515985
  5. Liu Z, Wang H, Sun C, He Y, Xia T, Wang J, vd. ZWZ-3, a Fluorescent Probe Targeting Mitochondria for Melanoma Imaging and Therapy [Internet]. C. 13, Frontiers in Pharmacology . 2022. Available at: https://www.frontiersin.org/article/10.3389/fphar.2022.829684
  6. Jin S-G, Padron F, Pfeifer GP. UVA Radiation, DNA Damage, and Melanoma. ACS omega. Eylül 2022;7(37):32936–48.
  7. Pfeifer GP. Correction to: Mechanisms of UV-induced mutations and skin cancer. Genome Instab Dis [Internet]. 2021;2(4):262. Available at: https://doi.org/10.1007/s42764-021-00037-y
  8. Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z, vd. Cancer stem cells: advances in knowledge and implications for cancer therapy. Signal Transduct Target Ther [Internet]. 2024;9(1):170. Available at: https://doi.org/10.1038/s41392-024-01851-y

Details

Primary Language

English

Subjects

Cancer Cell Biology

Journal Section

Review

Publication Date

June 10, 2025

Submission Date

September 24, 2024

Acceptance Date

January 27, 2025

Published in Issue

Year 2025 Volume: 64 Number: 2

Vancouver
1.Berrin Ozdil, Hüseyin Aktuğ. Cancer stem cells and the SHH pathway in malignant melanoma: Therapeutic implications. EJM. 2025 Jun. 1;64(2):415-23. doi:10.19161/etd.1555155

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.